Nivolumab adjuvant — post-CROSS without pCR (CheckMate-577)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | DRUG-NIVOLUMAB |
|---|
| ID | REG-NIVO-ADJUVANT-ESOPH |
|---|---|
| Type | Regimen |
| Status | reviewed 2026-04-26 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-ESMO-ESOPHAGEAL-2024 SRC-NCCN-ESOPHAGEAL-2025 |
Notes
CheckMate-577: post-CROSS-CRT-then-esophagectomy patients with residual ypT+ or ypN+ (no pCR) — adjuvant nivolumab × 1 year doubled DFS (22 vs 11 mo). Both adeno + squamous benefit. Initiation within 4-16 weeks post-surgery per protocol.
Used By
Indication
IND-ESOPH-ADJUVANT-NIVOLUMAB-POST-CROSS- IND-ESOPH-ADJUVANT-NIVOLUMAB-POST-CROSS